![Nicolas Leupin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Leupin
Geen lopende functies
Vermogen: 2 M $ op 31-07-2026
Profiel
Nicolas Leupin worked as Chief Medical Officer at argenx SE from 2016 to 2019 and at Molecular Partners AG from 2019 to 2023.
Also held the position of Chief Medical Officer at NovoCure Ltd. and was a Member of the Swiss Group for Clinical Research.
Education includes a doctorate from the University of Bern and an MBA from Jones International University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NOVOCURE LTD. 0,09% | 06-04-2026 | 102.979 ( 0,09% ) | 2 M $ | 31-07-2026 |
Eerdere bekende functies van Nicolas Leupin
| Bedrijven | Functie | Einde |
|---|---|---|
| MOLECULAR PARTNERS AG | Hoofd Techniek/Wetenschap/O&O | 24-08-2023 |
| ARGENX SE | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
| NOVOCURE LIMITED | Hoofd Techniek/Wetenschap/O&O | - |
Swiss Group for Clinical Research | Corporate Officer/Principal | - |
Opleiding van Nicolas Leupin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
28
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Jones International University
 Jones International University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bern
 University of Bern Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
NovoCure Ltd.
 NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Swiss Group for Clinical Research |
